Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tumors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infaretion, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.
Abstract: The present invention relates to methods for attenuating aging, of health maintenance, and/or treating, or delaying the onset of, an age-related condition or disorder, in a subject comprising administering to the subject an effective amount of (a) one or more compounds that sustain pharmacological activation of xenobiotic metabolism or induce fermentation by gut bacteria to produce substances that activate xenobiotic metabolism enzymes and/or stimulate xenobiotic excretion and (b) one or more chelators. A further aspect of the invention is a composition comprising (a) and (b).
Type:
Application
Filed:
April 27, 2020
Publication date:
August 13, 2020
Applicant:
Longevica Therapeutics Inc.
Inventors:
Alexey Ryazanov, Alexander Chikunov, Yuriy Shymkiv
Abstract: The synthesis of an organosilicone adsorbent, which can be used in medicine as an enterosorbent for the removal of organic and toxic metabolites from the body obtains a new branched organosilicone polymerous polynuclear adsorbent of high molecular toxins. According to the analysis by Si29NMR method, the adsorbent contains superpositions of at least three silicon signals with values of chemical shifts ?80 ppm, ?100 ppm, ?115 ppm, and ratio of their integral intensities close to 2:2:1. This adsorbent has a high adsorption activity, and the synthesis of its obtaining can reduce labour costs, increase output of the target product in manufacture and reduce their self-cost/net-cost.
Abstract: The present invention relates to a method of preventing or treating keloids using a liquid plasma. A liquid plasma according to the present invention is remarkably effective in inhibiting the generation and proliferation of keloids, thus being expected to be greatly utilized for the prevention and treatment of keloids.
Type:
Application
Filed:
August 23, 2018
Publication date:
August 13, 2020
Applicant:
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Abstract: This invention describes topical formulations for pain relief and sleep aid that utilizes potassium salts, as the active ingredient. More specifically, the invention relates to a topical pain relief and sleep aid formulation comprising a potassium ion, as the active ingredient, electrically balanced by an anion, wherein said anion is selected from the FDAs GRAS list.
Abstract: The present application relates to methods to administer to a patient a hypothermal inhalation gas composition that includes oxygen and a mixture of inert gases. The mixture of inert gases includes a first compound selected from xenon and argon, and a second compound having hypothermal properties, such as helium. In the methods, a gas composition including oxygen and a mixture of inert gases is selected and the gas composition is administered to the patient at an inhalation temperature of a specified range such that the body temperature of the patient is maintained within a specified temperature range.
Abstract: The present invention relates to a nanocomposite formulation for use in hemostasis comprising at least one calcium-silicate and at least one polysaccharide. The invention also relates to solvent-free process for preparation of the nanocomposite formulation.
Abstract: Provided are multiply functional telodendrimers. The telodendrimers can be used for combination drug delivery. The telodendrimers may have one or more crosslinking groups (e.g., reversible photocrosslinking groups). The telodendrimers can aggregate to form nanocarriers. Cargo such as combinations of drugs, imaging probes, and other materials may be sequestered in the core of the aggregates via non-covalent or covalent interactions with the telodendrimers. Such nanocarriers may be used in drug delivery applications and imaging applications.
Abstract: The invention relates to pharmaceutical compositions comprising a zinc2+ salt and a ?-polyglutamic acid carrier, and, optionally, an NF-?B inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. Methods include administering a liquid dosage form or a solid dosage form of a therapeutically effective amount of a Zn(II) salt and a ?-polyglutamic acid carrier to a patient in need thereof. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, using the disclosed compositions are provided. Tumors that respond to the pharmaceutical compositions disclosed herein include neuroendocrine (neuroblastoma), gastric, uterine, and lung tumors.
Abstract: This invention relates to a method for preparing compositions for preventing or treating microbial infections, compositions suitable for use in such treatments and methods for treatment or prevention of infections. One such composition finds particular use in treating mastitis in ruminants. The composition is administered into the udder of an animal as a highly effective treatment for mastitis, or as a prophylactic therapy, by means of an intra-mammary infusion. The milk produced by the animal, during treatment using the composition and method of the invention, is free of residues, such as antibiotics, antimicrobial agents or antimicrobial proteins, which could affect its suitability for drinking or in the production of milk products, such as cheese or yoghurt. The compositions and methods are also useful in treating and preventing lung infections; and infections in burns and wounds; and other infections caused by biofilms. The compositions may also be used on medical devices to prevent infection.
Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
Abstract: The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (e.g., doxorubicin), a topoisomerase inhibitor, an oxazaphosphinanyl anti-cancer agent, a nitro-aryl anti-cancer agent, a thiol-reactive functional group agent, a nitric oxide modulator, a platinum-based antineoplastic compound, acrylamide, acrylonitrile, bis(4-fluorobenzyl)trisulfide, a cardiac glycoside, an anti-mitotic agent (e.g., paclitaxel), a nucleoside analog, an EGFR inhibitor, or an anti-microbial agent.
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
April 3, 2020
Publication date:
August 13, 2020
Inventors:
Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
Abstract: Disclosed are methods of selectively expanding a number of T cells. The methods may comprise: modifying human T cells to express a TCR, wherein the TCR comprises a murine constant region; producing a population of cells comprising a number of human T cells expressing the TCR and a number of human T cells not expressing the TCR; and culturing the population of cells in the presence of (i) irradiated feeder cells, (ii) one or more cytokines, and (iii) an antibody, or an antigen-binding portion thereof, wherein the antibody has antigenic specificity for the murine constant region of the TCR, so as to selectively expand the number of T cells expressing the TCR over the number of T cells not expressing the TCR. Also disclosed are related populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
Type:
Application
Filed:
September 24, 2018
Publication date:
August 13, 2020
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Inventors:
Drew C. Deniger, Steven A. Feldman, Steven A. Rosenberg
Abstract: The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.
Abstract: The present disclosure is directed to compositions and methods to treat the inflammatory response present in certain diseases and illnesses by modifying a dysregulation of one or more genes associated with the Wnt/?-catenin signaling pathway. Embodiments of the disclosure can provide methods for treating an inflammatory response in a patient by identifying the inflammatory response and modifying the inflammatory response.
Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising an antigen-binding domain with an affinity in the range of 50 nM to 500 nM, wherein said affinity comprises component kinetics such that the association rate constant (kon) is greater than or equal to 1×105 M?1 S?1, and/or the dissociation rate constant (koff) is greater than or equal to 0.01 s?1.
Type:
Application
Filed:
February 20, 2020
Publication date:
August 13, 2020
Inventors:
Martin Pulé, Anne Kramer, Evangelia K. Kokalaki
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
April 17, 2020
Publication date:
August 13, 2020
Inventors:
Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
Abstract: A family of chimeric antigen receptors (CARs) containing a CD123 specific scFv was developed to target different epitopes on CD123. In some embodiments, such a CD123 chimeric antigen receptor (CD123CAR) gene includes an anti-CD123 scFv region fused in frame to a modified IgG4 hinge region comprising an S228P substitution, an L235E substitution, and optionally an N297Q substitution; a costimulatory signaling domain; and a T cell receptor (TCR) zeta chain signaling domain. When expressed in healthy donor T cells (CD4/CD8), the CD123CARs redirect T cell specificity and mediated potent effector activity against CD123+ cell lines as well as primary AML patient samples. Further, T cells obtained from patients with active AML can be modified to express CD123CAR genes and are able to lyse autologous AML blasts in vitro. Finally, a single dose of 5.0×106 CAR123 T cells results in significantly delayed leukemic progression in mice.
Type:
Application
Filed:
April 27, 2020
Publication date:
August 13, 2020
Inventors:
Stephen J. Forman, Armen Mardiros, Christine E. Brown, Uma Maheswara Rao Jonnalagadda
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, and a stem cell therapeutic agent for treating rheumatoid arthritis, comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient. Nasal inferior turbinate-derived mesenchymal stem cells of the present invention have the effects of reducing the production of interleukin-17A (IL-17A), tumor necrosis factor-? (TNF-?), immunoglobulin G2 (IgG2a) which is an inflammation-inducing factor, and/or the proliferative ability of lymph node T cells, increasing interleukin-10 (IL-10) and/or regulatory T-cells (Treg, CD4+CD25+foxp3+ cell) that contribute to immune tolerance in spleen cells, and inhibiting the proliferation of human T-cells.
Type:
Application
Filed:
June 21, 2018
Publication date:
August 13, 2020
Inventors:
Sung Won KIM, Seung Ki KWOK, Jaeseon LEE, Sun hwa PARK, Jung Yeon Lim
Abstract: Methods of treating an ischemic disease in a subject are provided. Accordingly there is provided a method comprising administering to the subject a therapeutically effective amount of cells with reduced level of expression and/or activity of TNFR1, thereby treating the ischemic disease in the subject. Also provided is a method comprising treating with TNFalpha cells with reduced expression and/or activity of TNFR1 and administering to the subject a therapeutically effective amount of said cells, thereby treating the ischemic disease in the subject.
Abstract: An agent for promoting migration of pluripotent stem cells containing an extract from inflamed tissues inoculated with vaccinia virus. An extract from inflamed tissues inoculated with vaccinia virus promotes migration of Muse cells. Thus, the agent for promoting migration of pluripotent stem cells for various diseases to which migration of pluripotent stem cells may have an advantageous effect.
Abstract: This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including formulations that effectively preserve microbial cell viability during freeze-thaw or freeze-drying. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disordor, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.
Abstract: Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable Gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.
Abstract: The invention relates to combined multistage microbial preparations that are effective for enhancement of the biological skin barrier and maintenance of healthy skin microbiota. The preparations might be used as cosmetic or medicinal products. Combined multistage microbial cosmetic product are intended for an invigoration of the natural biological reinforcement barrier on the skin and mucosal surfaces weakened in case of chronic problems associated with dysbiosis such as atopic dermatitis, acne, rosacea and vitiligo or acute problems caused by damage of the skin such as burns, cuts and contusions.
Type:
Application
Filed:
February 11, 2020
Publication date:
August 13, 2020
Inventors:
Karel BEZOUSKA, Jan ENGL, Lubomir JANDA, Adam NOREK
Abstract: The present invention provides a reducing cholesterol probiotic strain, composition thereof and use thereof. The probiotic strain is Lactobacillus plantarum, which itself and its metabolites can effectively reduce the cholesterol content, enhance the gene expression level of SCARB1, APOA1, and LDLR to promote the effect of cholesterol metabolism, and can effectively reduce the total cholesterol and the low-density lipoprotein in human blood.
Abstract: A composition including at least one selected from the group consisting of the APsulloc 331261 (accession number: KCCM11179P) strain of Lactobacillus plantarum, a lysed product thereof, a culture thereof, and an extract thereof is disclosed. The composition has an activity of improving or treating disorders of the digestive system caused by alcohol or inflammation to facilitate the recovery of and improve the welfare of relevant patients. A method of preventing, improving, or treating gastrointestinal disorders by using the composition is disclosed.
Type:
Application
Filed:
August 9, 2018
Publication date:
August 13, 2020
Applicants:
Amorepacific Corporation, HANDONG GLOBAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Juyeon SEO, Donghyun CHO, Wangi KIM, Wilhelm HOLZAPFEL, Yosep JI, Haryung PARK, Hyeonrae KIM
Abstract: Lactobacillus plantarum TCI378 is provided. The Lactobacillus plantarum TCI378 was deposited at German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen and Zellkulturen, DSMZ) under the accession number DSM 32451. A method for losing fat and/or improving gastrointestinal functions is also provided. The method comprises administering to a subject in need an effective amount of a composition, wherein the composition comprises Lactobacillus plantarum TCI378 and/or its metabolites.
Type:
Application
Filed:
April 21, 2020
Publication date:
August 13, 2020
Inventors:
Yung-Hsiang LIN, Chu-Han HUANG, Cheng-Yu HO
Abstract: The invention relates to the production of phage and non-replicative transduction particles using DNAs (eg, plasmids and helper phage, mobile genetic elements (MGEs) or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these. The non-replicative transduction particles can be used to deliver antibacterial agents comprising a guided nuclease system.
Abstract: Provided are an enterovirus D68 (EV-D68) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the EV-D68 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, or a pharmaceutical composition comprising the EV-D68 or a modified form thereof, or the nucleic acid molecule, and use of the EV-D68 or a modified form thereof, or the nucleic acid molecule in the manufacture of a pharmaceutical composition for treating a tumor.
Type:
Application
Filed:
July 18, 2018
Publication date:
August 13, 2020
Applicants:
XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.
Inventors:
Tong CHENG, Wei WANG, Junkai WAN, Wenkun FU, Xiangzhong YE, Jun ZHANG, Ningshao XIA
Abstract: Provided herein are methods of treating a subject with triple negative breast cancer or colorectal cancer. In exemplary embodiments, the method comprises administering to the subject a combination of an oncolytic virus, such as talimogene laherparepvec, and an anti-PD-L1 antibody, such as atezolizumab. In exemplary aspects, the oncolytic virus is administered to the subject at an initial dose followed by a second dose, wherein the initial dose is lower than the second dose. In exemplary aspects, the oncolytic virus is intrahepatically administered to the subject.
Type:
Application
Filed:
August 6, 2018
Publication date:
August 13, 2020
Inventors:
Jennifer Lorraine Gansert, Sumita Shankar Bhatta, Joseph Paul Woodard, JR., Edward Namserk Cha
Abstract: A pharmaceutical composition containing cannabis for improving the quality of sleep in a patient is provided. Also provided are a use of the pharmaceutical composition for improving the quality of sleep in a patient, and methods for improving the quality of sleep. The pharmaceutical composition preferably includes a combination of therapeutically effective amounts of one or more of the following medicinal ingredients: cannabis, and/or an herb.
Abstract: A pharmaceutical composition containing cannabis for improving the quality of sleep in a patient is provided. Also provided are a use of the pharmaceutical composition for improving the quality of sleep in a patient, and methods for improving the quality of sleep. The pharmaceutical composition preferably includes a combination of therapeutically effective amounts of one or more of the following medicinal ingredients: cannabis, and/or an herb.
Abstract: A pharmaceutical composition containing cannabis for increasing energy levels and/or alleviating fatigue in a patient. Also provided are a use of the pharmaceutical composition for increasing energy levels and/or alleviating fatigue in a patient, and methods for increasing energy levels and/or alleviating fatigue. The pharmaceutical composition preferably includes a combination of therapeutically effective amounts of one or more of the following medicinal ingredients: cannabis, an herb, vitamins, and/or fructose.
Abstract: Rapid onset and extended action plant-based medicinal compounds or nutritional supplements and synthetic cannabinoid formulations are described. Rapid onset is provided by N-acylated fatty amino acids and/or penetration enhancers. Extended action can be provided by one or more sustained-release systems.
Abstract: Disclosed here are compositions comprising powered hemp seed, an emulsified/dispersant such as lecithin (particularly soy or sunflower lecithin), Cannabis, and optionally other additives and excipients, and the methods of making these compositions. The compositions may be used for, for instance, in the treatment of pain and for their anti-emetic (anti-nausea and anti-vomiting) properties, as well as for appetite enhancement and the treatment of anorexia. Kits containing the compositions, arranged for proper sequential dosing, and optionally including instructions for use, are also disclosed.
Abstract: The present invention relates to a composition comprising or, alternatively, consisting of an effective amount of a mixture which comprises at least, or consists of: a) an extract of Pelargonium sidoides; b) an extract of Adhatoda vasica; and c) N-acetyl cysteine for use in a method for the preventive or therapeutic treatment of at least one respiratory tract disorder in a subject, wherein said treatment method comprises the administration of said composition to the subject.
Abstract: The present invention relates to novel herbal pharmaceutical compositions and method of preparing said herbal pharmaceutical compositions. Said novel composition along with therapeutic agents and pharmaceutically acceptable carriers, pharmaceutically acceptable bases or combinations thereof, is useful for the treatment of ano-rectal diseases, including hemorrhoids, anal fissures, fistula etc. The novel compositions possess properties to control inflammation by lowering levels of inflammatory cytokines and matrix metalloproteinases, prevent capillary bleeding and fragility in mammalians, particularly human beings and have wound healing properties.
Abstract: The present application relates to solid pharmaceutical compositions and solid dosage forms containing them which comprise oils as their active pharmaceutical ingredient. Methods of preparing the compositions and their uses as described.
Type:
Application
Filed:
July 6, 2017
Publication date:
August 13, 2020
Inventors:
Christian VON CORSWANT, Romain BORDES, Simon Peter Michael HJELM JONASSON
Abstract: The present invention relates to an organoleptically improved dietary fiber composition comprising Trigonella foenum-graecum (fenugreek) seeds in the form of flakes with improved palatability, and method(s) of preparing the said composition. More particularly, invention relates to nutrient rich de-bitterised and de-fatted fenugreek dietary fiber and administering the same in a subject to bring satiety, feeling of fullness, appetite suppression, less desire to consume food, which may further lead to reduction or management of weight. The present invention can be used for the development of functional food, dietary plan and as a nutritional supplement. The present invention also relates to methods of managing various conditions such as, but not limited to, management of weight, appetite scores, glucose homeostasis, body mass index and serum insulin levels or any combinations thereof using the said composition.
Type:
Application
Filed:
February 10, 2020
Publication date:
August 13, 2020
Applicant:
BIOGEN EXTRACTS PRIVATE LIMITED
Inventors:
Jai Shankar Raghava Chandra, Sujit Mukund
Abstract: The present invention relates to a composition comprising ?-lipoic acid, Salvia miltiorrhiza extract and Curcumin, optionally further comprising ?-linolenic acid or borage oil. Furthermore, the present invention relates to the use of such composition for treating neuropathies.
Abstract: Methods of treating, suppressing, or reducing the severity of a liver cancer in a subject are described herein. The disclosed methods include administering to the subject a first amount of safranal or a pharmaceutically acceptable pro-drug thereof and administering to the subject a second amount of a TOP1 inhibitor. In some embodiments, the TOP1 inhibitor is irinotecan, topotecan, camptothecin, lamellarin D, and/or combinations thereof.
Abstract: The disclosure relates to intravenous formulations of GLYX peptides for treating CNS Disorders such as depression, neuropathic pain, or anxiety.
Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
Type:
Application
Filed:
February 14, 2020
Publication date:
August 13, 2020
Inventors:
Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
Abstract: The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosting gall bladder-related disorders using sincalide formulations.
Type:
Application
Filed:
April 27, 2020
Publication date:
August 13, 2020
Applicant:
BRACCO DIAGNOSTICS INC.
Inventors:
Edmund C. METCALFE, Jo Anna MONTEFERRANTE, Margaret NEWBORN, Irene KUCHAREWICZ ROPIAK, Ernst SCHRAMM, Gregory W. WHITE, Julius P. ZODDA
Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.
Type:
Application
Filed:
June 24, 2016
Publication date:
August 13, 2020
Applicants:
Eastern Virginia Medical School, Eriko Life Sciences Ventures, LLC, Children's Health Foundation, Inc., Eriko Life Sciences Ventures, LLC
Abstract: The present invention relates to compositions comprising daptomycin and at least one amino acid, methods of providing such compositions and the uses thereof.
Type:
Application
Filed:
August 28, 2018
Publication date:
August 13, 2020
Inventors:
Anita BEVETEK MOCNIK, Stipica TOMIC, Barbara FUMIC